When initial HER2 testing provides equivocal results, performing FIHS testing with CSI’s HER2/D17S122 probe set can provide results that can be used to qualify patients for therapy. The goal of the alternative probe assay is to better stratify patients as positive or negative for receiving HER2 targeted therapy.
CSI’s Multiple Myeloma Assessment Protocol (MMAP) is a specialized process utilizing flow cytometry, FISH, and cytogenetic testing to provide diagnostic and prognostic information for plasma cell neoplasms. The MMAP protocol utilizes a CD138 enrichment process to isolate plasma cells necessary for FISH testing.
CSI also offers C•FISH, CSI’s exclusive, revolutionary tech-only FISH product. C•FISH offers unique advantages like; on-screen cut off ranges for heme cases, comprehensive image gallery with up to 300 images per case and our HER2 system allows users the ability to sign out both breast and non-breast cases – all with on-screen reference tables.
Available FISH Assays
Solid Tumor Assays